Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)
NCT02003573 · Boehringer Ingelheim · PHASE1 · terminated · last registry update 2019-01-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Boehringer Ingelheim |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DNMT3A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-01-18Phase 3 first posted: Sellas Life Sciences Group, Galinpepimut-S + Azacitidine (NCT04229979)
- 2020-01-02Results posted on the registry: M.D. Anderson Cancer Center, Eltrombopag + Decitabine (NCT02010645)
- 2020-01-02Also stopped (terminated): M.D. Anderson Cancer Center, Eltrombopag + Decitabine (NCT02010645)
- 2019-12-03Also stopped (terminated): National Cancer Institute (NCI), Celebrex + Tumor cell vaccine (NCT01258868)
- 2019-11-21Also stopped (terminated): Pfizer, PF-06747143 + Cytarabine (NCT02954653)
- 2019-11-15Results posted on the registry: Gilead Sciences, Entospletinib + Daunorubicin (NCT02343939)
- 2019-11-15Also stopped (terminated): Gilead Sciences, Entospletinib + Daunorubicin (NCT02343939)
- 2019-10-10Phase 3 first posted: Nanfang Hospital, Southern Medical University, Decitabine + Busulfan (BU) (NCT04123392)
- 2019-09-23Phase 3 first posted: Nanfang Hospital, Southern Medical University, Decitabine + Busulfan (BU) (NCT04098653)
- 2019-09-12Phase 3 first posted: The First Affiliated Hospital of Soochow University, Decitabine plus HAAG regimen + Idarubicine plus Cytarabine regimen (NCT04087967)
- 2019-09-10Phase 3 first posted: The First Affiliated Hospital of Soochow University, Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF (NCT04083911)
- 2019-08-21Also stopped (terminated): Milton S. Hershey Medical Center, Avelumab (NCT03395873)
- 2019-08-07Results posted on the registry: Mayo Clinic, Decitabine + Midostaurin (NCT02634827)
- 2019-08-07Also stopped (terminated): Mayo Clinic, Decitabine + Midostaurin (NCT02634827)
- 2019-06-17Results posted on the registry: Janssen Research & Development, LLC, Phase1 and Phase 2: decitabine + Phase 1: cytarabine (NCT01853228)
- 2019-06-17Also stopped (terminated): Janssen Research & Development, LLC, Phase1 and Phase 2: decitabine + Phase 1: cytarabine (NCT01853228)
- 2019-05-22Results posted on the registry: University of Wisconsin, Madison, decitabine + fludarabine phosphate (NCT01707004)
- 2019-05-10Results posted on the registry: M.D. Anderson Cancer Center, Decitabine + Idarubicin (NCT01794702)
- 2019-05-08Phase 3 first posted: AbbVie, Venetoclax + Azacitidine (NCT03941964)
- 2019-05-06Also stopped (withdrawn): M.D. Anderson Cancer Center, Group 1: TK216 + Group 2: TK216 (NCT03752138)
- 2019-04-24Phase 3 first posted: Delta-Fly Pharma, Inc., DFP-10917 + Cytarabine (NCT03926624)
- 2019-03-18Results posted on the registry: Pfizer, PF-06747143 + Cytarabine (NCT02954653)
- 2019-02-28Results posted on the registry: Janssen Research & Development, LLC, Decitabine 20 mg/m^2 + Talacotuzumab 9 mg/kg (NCT02472145)
- 2019-01-10Phase 3 first posted: Peking University People's Hospital, Decitabine + mBU/CY and ATG (NCT03799224)
- 2019-01-04Phase 3 first posted: Peking University People's Hospital, Decitabine + mBU/CY and ATG (NCT03793517)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision